Governance Task Force

Complete GTF Report (Member Login)

We are pleased to announce that the Governance Task Force’s recommendations were not only unanimously approved by the Board of Directors, but that the proposed bylaws changes needed to fully enact their recommendations were approved by the membership.

The Governance Task Force (GTF) was created in Spring 2018 after our new strategic plan (SP4), was approved. The GTF explored how a new governance approach can enrich member engagement experiences, increase volunteer opportunities, and ensure that the Society’s top member leaders reflect the rich diversity of our members and have the professional and personal skillsets to lead our organization into the future.

Top 3 Reasons for Our Governance Review

Supporting Strategic Plan Implementation—We are most successful when our priorities, strategy, and resources are aligned...

Unifying the Endocrine Community—Endocrinology is a dynamic field and constantly evolving—so is our membership...

Member Engagement—Our members are passionate about endocrine science, education, and promoting optimal health and well-being...

Read Top 3 Reasons for Governance Review

Our new mission is to unite, lead, and grow the endocrine community to accelerate scientific breakthroughs and improve health worldwide; the GTF’s charge was to make that mission a reality by recommending a model that ensured that the right leaders are in the right roles at the right time.

What is “Governance?”

“Governance” is the structure and process by which an organization makes decisions that help it achieve its mission. This includes the physical makeup of an organization’s legal governing body (board of directors), its member and staff leaders, and how the work of an organization is completed.

To learn more about governance, please see our resources section where you can find readings on contemporary association governance practices.

Who served on the GTF?

The GTF was carefully composed of 21 members who represent our Society’s valued diversity. The GTF members span career stages, ages, genders, professional roles, endocrine specialties, and locations around the world.


John Newell-Price, MD, PhD, FRCP

"The GTF used a rigorous and detailed process to come up with a set of recommended changes that strengthen and enhance the governance and leadership of the Endocrine Society. As a result, the Society will be better placed to deliver on its strategic mission, now and in the coming years." —John Newell-Price, MD, PhD, FRCP


Where Are We Now?

The GTF recommendations were unanimously approved by Council (now known as the Board of Directors) in March 2019 and sent to the membership for bylaws ratification in April 2019. The bylaws were ratified by the membership, and we are now in the beginning phases of implementing the GTF recommendations in full.

What was the GTF's Process?

The GTF first met in person June 2018 in Washington, D.C. where it hosted a joint workshop with Council and task force guests to learn about contemporary association governance and to identify the guiding principles which serve as a guidepost for discussions. The GTF continued their work over the summer by collaborating virtually and participating on several conference calls. The GTF met again in September 2018 in Miami, Florida to discuss next steps in drafting recommendations.

From March 2018-November 2018, the GTF reached out to members to share preliminary thinking and receive feedback. This member input was critical to ensure that the GTF heard multiple viewpoints and ideas, and to hear and allay any concerns. The member feedback included:

  • 2,941 members and Society stakeholders responded to a survey that included governance-related questions
  • Focus groups of 29 members were held at ENDO 2018 and CEU Miami 2018
  • Three webinars were held in September 2018: all members with a history of committee, task force, Council, and/or Nominating Committee involvement were invited. The 53 members who participated received a survey to provide additional comments.
  • After the September 2018 webinars, a governance webpage was pushed via Endocrine e-news to all members. It included a recorded webinar, the feedback survey, governance readings and resources, and the GTF roster.
  • Webinars were held in October 2018 (for the Nominating Committee) and November 2018 (two for members, especially basic scientists).
  • In totally, approximately 3,000 members responded to this outreach effort and provided insight.

In September and November 2018, the GTF met, both with Council and alone, and used member feedback to develop recommendations. From December 2018 to February 2019, the GTF collaborated virtually and with conference calls to finalize this report, which was presented to the Endocrine Society Council in March 2019 for approval. The Council (henceforth known as the Board of Directors) unanimously approved the recommendations and presented the required bylaws changes needed to implement the GTF recommendations in full to the membership for approval in April 2019.


"A core strength of the Endocrine Society has always been its members and the tremendous science they perform and clinical care they provide.  But our membership, their needs, and the way they contribute to the Society is constantly evolving and to keep pace Society governance must co-evolve.  The recommendations of the GTF recognize the need for governance to support the changing needs of Society members, so as to continue to advance our collective mission."
Kelly Mayo, PhD


What are the Task Force Recommendations?

Summary of Recommendations

The following core governance changes were proposed for Council approval in March 2019. The GTF believes that this structure will provide an inclusive and responsive approach to leading our Society forward that meets the needs of our diverse membership.

  1. Structure of the Governing Body and Selection of Leaders
    1. Change the name of the governing body from “Council” to “Board of Directors.”
    2. Retain the size of the current Council, with the following composition:
      1. Officers: President, President-elect, Immediate Past President (Presidential Officers), and Secretary-Treasurer
      2. 11 at-large voting Directors with 3-year staggered terms, broadly representative of membership
      3. CEO, Nominating Committee Chair, and Early Career representative as ex-officio, non-voting members
    3. Retain an Executive Committee comprised of i. President, President-elect, Immediate Past President (Presidential Officers), and Secretary-Treasurer, voting
      1. Secretary-Treasurer Designate (when applicable), and CEO as ex officio, non-voting
    4. Implement a new approach to selecting leaders i. Members continue to elect the President-Elect from a slate of two candidates proposed by the Nominating Committee
    5. Nominating Committee will appoint the Secretary-Treasurer, Board of Directors, and Early Career representative, ensuring broad representation of the membership
    6. Outgoing Board members must wait one year before serving on the Nominating Committee
  2. Structure and Selection of Nominating Committee
    1. The Board of Directors will appoint the Nominating Committee members
    2. 15 voting members of the Nominating Committee
    3. The CEO, and the outgoing Immediate Past President in the year after leaving the Board, will serve as ex-officio, non-voting members
    4. The Committee charge, priorities, and qualifications for membership will be updated
    5. Outgoing Committee members must wait two years before serving on the Board of Directors
  3. Leadership Pipeline
    1. Sunset the use of constituencies to define members and leadership positions and expand member profiles to include more comprehensive information about professional roles and other personal and professional characteristics.
    2. A comprehensive approach for cultivating and evaluating leaders will be instituted.
    3. A Basic Science Advisory Group will advise the Board on how to support the basic scientists in the Society and will be asked to nominate individuals to leadership positions.
  4. Workforce – Moving forward, the Council will actively evaluate the Society’s workgroup structure and prioritize initiatives of the Society in light of SP4.

To access a GTF Report Summary, please click here.

To access the Complete GTF Report, please click here.
(Member Login Required)

Discussion

“Observations on Expanded Professional Profiles—Lindsey Trevino, PhD and E. Dale Abel, MD, PhD”


“Leadership Pipeline Support Genevieve Neal-Perry, MD, PhD”


“Reflections on the GTF Recommendations E. Dale Abel, MD, PhD

Resources

The Governance Task Force has created Frequently Asked Questions as a resource for members.

Please email governance@endocrine.org to submit a question or comment to the GTF.

GTF Roster

  • Lynnette Nieman, MD
  • Dale Abel, MBBS, MD, PhD (Ex-Officio member)
  • Henry Anhalt, DO
  • Cesar Luiz Boguszewski, MD, PhD
  • Samantha Butts, MD, MSCE
  • Gary Hammer, MD, PhD
  • Ken Ho, MD
  • Ursula Kaiser, MD, BSC
  • Susan Mandel, MD, MPH (Ex-Officio member)
  • Kelly Mayo, PhD
  • Genevieve Scott Neal-Perry, PhD, MD
  • John Newell-Price, MD, PhD, FRCP
  • Daniel Oppenheim, MD, PhD
  • Al Powers, MD
  • Nalini Shah, DM
  • Carolyn Smith, PhD
  • Gabriel Smolarz, MD, MS, FACE, ECNU, DIpl. ABOM
  • Lindsey Starr Treviño, PhD
  • AJ Van der Lely, MD, PhD
  • Mayumi Yamamoto, MD, PhD, MBA
  • Barbara Byrd Keenan, FASAE, CAE (Ex-Officio member)